| Literature DB >> 30668190 |
Jun Wang1, David Van Den Berg1, Amie E Hwang1, Daniel Weisenberger2, Timothy Triche3,4, Bharat N Nathwani5, David V Conti1, Kim Siegmund1, Thomas M Mack1,6, Steve Horvath7, Wendy Cozen1,6.
Abstract
DNA methylation (DNAm) silences gene expression and may play a role in immune dysregulation that is characteristic of adolescent/young adult Hodgkin lymphoma (AYAHL). We used the Infinium HumanMethylation27 BeadChip to quantify DNAm in blood (N = 9 pairs, mean age 57.4 y) or saliva (N = 36 pairs, mean age 50.0 y) from long-term AYAHL survivors and their unaffected co-twins. Epigenetic aging (DNAm age) was calculated using previously described methods and compared between survivors and co-twins using paired t-tests and analyses were stratified by sample type, histology, sex, age at sample collection and time since diagnosis. Differences in blood DNAm age were observed between survivors and unaffected co-twins (64.1 vs. 61.3 years, respectively, p = .04), especially in females (p = .01); no differences in saliva DNAm age were observed. Survivors and co-twins had 74 (in blood DNA) and 6 (in saliva DNA) differentially methylated loci. Our results suggest persistent epigenetic aging in AYAHL survivors long after HL cure.Entities:
Keywords: AYA; DNA methylation; Hodgkin lymphoma; blood; saliva; survivors; twins
Mesh：
Substances：
Year: 2019 PMID： 30668190 PMCID： PMC7781082 DOI： 10.1080/10428194.2018.1533128
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022